Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 16/20 | 0.71 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30239531 | 1.00 | EHMT2 (0.71) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL30063339 | 0.92 | EHMT2 (0.62) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL20745680 | 0.92 | EHMT2 (0.62) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL20746263 | 0.89 | EHMT2 (0.61) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL30239309 | 0.89 | EHMT2 (0.61) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL22654144 | 0.88 | EHMT2 (0.72) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL30238795 | 0.88 | EHMT2 (0.72) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL22654201 | 0.88 | EHMT2 (0.72) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL30239270 | 0.88 | EHMT2 (0.72) | EHMT2ACHENPC1RAB9AAPP | |
| SCHEMBL20746170 | 0.87 | EHMT2 (0.59) | EHMT2ACHENPC1RAB9AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | EHMT2 2/4885ACHE 2215/4885NPC1 2468/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | EHMT2 2/4885ACHE 2215/4885NPC1 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.